EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Ensuring Ethics in AI-Driven Drug Safety
Senior Director of Pharmacovigilance and Risk Management at Curis Inc.
Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc with over years of experience in drug safety He is also leading the Innovation Working Group at the North American Society of Pharmacovigilance NASoP his expertise in combining technological innovation with patient safety makes him uniquely qualified to address the ethical challenges of AI implementation in pharm...
Articles
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
The traditional pharmaceutical approach of designing a diseasesymptomspecific drug has historically proven effective However this methodology often falls short due to the complex and often multifactorial etiology of diseases
Research Insights
Spectrophotometric And Spectroscopic Studies On Charge Transfer Complexes Of Antifungal Drug Clotrimazole
Abstract Clotrimazole CLZ is an imidazole derivative which is therapeutically used as an antifungal drug The routine control analysis of CLZ requires rapid reliable accurate and precise methods for the quantification of drug in its pharmaceutical formulations Spectrophotometric methods are presented for the determination of antifungal agent which were bas
Case Studies
A Dose-Escalation Case Study Of A Second-Generationnon-Ansamycin HSP90 Inhibitor, Onalespib (AT13387), Incombination With Imatinib In Patients With Metastaticgastrointestinal Stromal Tumour
Abstract Gastrointestinal stromal tumours GIST are commonly driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinases Although the initial response rates for newly diagnosed GIST to the tyrosine kinase inhibitorTKI imatinib can be most tumours ultimately become resistant commonly through secondary mutations or through alternative pa
Techno Trends
First-of-its-Kind SYFOVRE™ (pegcetacoplan injection) Developed for Geographic Atrophy (GA)
Apellis Pharmaceuticals developed SYFOVRE pegcetacoplan injection for the treatment of secondary agerelated macular degeneration AMD SYFOVRE pegcetacoplan injection is the only therapy approved for geographic atrophy GA By targeting C pegcetacoplan is designed to provide comprehensive control
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Unlocking New Avenues in Cancer Therapy by Targeting Ubiquitin-Specific Proteases
Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.
Peptide-Drug Conjugates in Precision Oncology
Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.
Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.
Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.
Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”
Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.
The Growing Role of Biocatalysis in Industrial Synthesis
Dr Reuben Carr has over 25 years of experience in developing proprietary biocatalytic processes for fine chemical and pharmaceutical manufacturing. He specialises in using directed evolution to engineer natural enzymes to carry out novel chemical reactions, enabling the synthesis of challenging molecular targets for clients and customers.
Homeopathic Science
Aditya Dilipkumar Patil pursed B.H.M.S. and MD (Hom) from Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College and Post Graduate Research Centre, Pune. He is currently working as Assistant Professor in Department of Homoeopathic Pharmacy at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018. He is a member of Chandrabhaga Charitable trust since 2017 and Life member of Moredada Charitable Trust, Nashik, Department of Herbal Medicine since 2018. He was working as Senior Research Fellow in Central Council for Research in Homoepathy (CCRH under Ministry of AYUSH). His main research work focuses on Evidenced based medicine, Diabetes, preclinical studies (In-vitro & In-vivo), nanoparticle etc.
Parth Sanjeev Aphale pursed B.H.M.S. from Dhondumama Sathe Homoeopathic Medical College and Research Centre, Pune and MD (Hom) from Foster Development Homoeopathic Medical College, Aurangabad. He is currently working as Professor in Department of Homoeopathic pharmacy at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018.
Dharmendra Basudeo Sharma pursed B.H.M.S. from Dhondumama Sathe Homoeopathic Medical College and Research Centre, Pune and MD (Hom) from University of Rajasthan and Ph.D from Maharashtra University of Health Science (MUHS). He is currently working as Principal and Head of Institute at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018.
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
press releasesRead more...
Insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab
Insitro the AI company unlocking causal human biology to systematically generate highimpact therapeutics today announced that the advanced machine learning models that insitro built with Eli Lilly
Lotus Pharmaceutical Announces Completion of UroVaxom® Product Rights Acquisition in South Korea
Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange a global pharmaceutical company headquartered in Taiwan today announced the completion of the acquisition of the South Korea product rights
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
XtalPi Holdings Limited HKEX an AI and roboticsdriven drug and materials discovery company today debuted Kodexia the industrys first closedloop small interfering RNA siRNA
ITOCHU Announces Strengthening of Drug Development Support Through the Use of AI-Driven Drug Discovery Technologies
ITOCHU Corporation announced today that it has signed a capital alliance agreement with MOLCURE Inc headquartered in Kawasaki City Kanagawa Prefecture Satoshi Tamaki Representative Director
GC Cell and QuantHealth Collaborate to Optimize Clinical Development of GCC2005
GC Cell a leader in the cell and gene therapy CGT sector within the biopharmaceutical industry and QuantHealth the global leader in AIpowered clinical trial simulation have announced a collaboratio
EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
EpiSign Inc and Geneyx Genomex Ltd today announced a partnership to advance the integration of genomic and epigenomic analysis for raredisease interpretation
EventsRead more...
12 - 13
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
12 - 13
Oct 20262nd International Conference on Drug Discovery
Village Hotel Changi, Singapor...
14 - 15
Oct 2026PDA Aseptic Manufacturing Excellence Conference
Pullman East Melbourne, Austra...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
LATEST NEWSRead more...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation
Halozyme Expands argenx Collaboration to Include Two Additional Development Targets
Halozyme Therapeutics has expanded its global collaboration and licence agreement with argenx to develop and commercialise subcutaneous formulations for two additional exclusive targets using its ENHANZE drug delivery technology
CSL and Alentis Partner to Advance Lixudebart for Rare Kidney and Liver Diseases
CSL and Alentis Therapeutics have entered into a global collaboration to jointly develop and commercialise lixudebart an investigational treatment that targets claudin and could have applications across several kidney liver and other diseases
Regeneron and Sanofi Expand Collaboration to Develop Long-Acting Immunology Antibodies
Regeneron Pharmaceuticals and Sanofi have expanded their longstanding antibody collaboration to develop and commercialise a new group of longacting immunology treatments
SK pharmteco Announces $200 Million Investment to Expand Manufacturing Capacity
SK pharmteco has announced a fiveyear investment of more than million to expand and upgrade its development and manufacturing capabilities in the US focusing on small molecules and peptides
CAS and Novartis Collaborate to Advance AI-Ready Reaction Data
CAS has announced a collaboration with Novartis Biomedical Research to improve access to reaction data and support the use of artificial intelligence in scientific research